NEUROCRINE BIOSCIENCES INC. 2023-2024 Proxy Voting Records

Description as filed by funds: Election of Directors: Christine A. Poon

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Christine A. Poon”): 80,898,676 for, 4,766,533 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 140 asset managers below reported 35,452,486 for, 1,287,740 withheld, 5,707 abstained, 7,000 unknown.

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

Description as filed by funds: Election of Directors: George J. Morrow

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: George J. Morrow”): 80,403,845 for, 5,261,364 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 140 asset managers below reported 34,900,437 for, 1,810,860 withheld, 34,636 abstained, 7,000 unknown.

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

Description as filed by funds: Election of Directors: Leslie V. Norwalk

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: Leslie V. Norwalk”): 76,902,461 for, 8,762,748 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 90% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 140 asset managers below reported 33,308,901 for, 3,193,414 withheld, 250,618 abstained.

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

Description as filed by funds: Election of Directors: William H. Rastetter, Ph.D.

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“Elect Director: William H. Rastetter, Ph.D.”): 72,381,261 for, 13,283,948 withheld, per its Form 8-K filed May 23, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The four nominees for Class I Director were elected.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 140 asset managers below reported 32,818,406 for, 3,742,990 withheld, 191,537 abstained.

Showing the 25 largest of 140 asset managers. See all 140 in the interactive database.

Description as filed by funds: To approve an amendment of the Company's 2020 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 3,635,000 shares; and

The 122 asset managers below reported 32,248,109 for, 1,813,928 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Advisory vote on the compensation paid to the Company's named executive officers;

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis. • Approval of the Amended 2020 Plan.”): 76,076,416 for, 9,499,523 against — passed, per its Form 8-K filed May 23, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The compensation of the Company's named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 139 managers: 36,429,690 for, 270,527 against, 49,665 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 461 managers: 54,042,596 for, 2,976,452 against, 732,305 abstained, 1,766 not voted, 19 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: TO RATIFY THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.

NEUROCRINE BIOSCIENCES INC.’s own tally for this item (“The Amended 2020 Plan was approved. • Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 84,641,389 for, 5,451,051 against — passed, per its Form 8-K filed May 23, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Amended 2020 Plan was approved.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 143 asset managers below reported 36,620,229 for, 113,581 against, 49,665 abstained.

Showing the 25 largest of 143 asset managers. See all 143 in the interactive database.